ByteDance, known for TikTok’s powerful recommendation algorithm, is now applying generative AI in drug discovery through its unit Anew Labs. At a major immunology conference in Boston, Anew Labs revealed its first AI-designed small molecule that targets IL-17, a protein-protein interaction long deemed undruggable, marking a significant step in developing oral treatments for autoimmune diseases.
- AI-designed molecule targets IL-17, an undruggable protein involved in autoimmune diseases.
- AnewOmni framework trained on 5 million biomolecular complexes to design functional molecules.
- Focus on developing oral small molecule therapies to replace injectable antibody drugs.
What happened
ByteDance’s drug discovery division, Anew Labs, showcased its first AI-designed therapy at the American Association of Immunologists’ annual meeting in Boston. The therapy comprises a generative AI-designed small molecule that inhibits IL-17, a protein implicated in several autoimmune diseases. This approach targets protein-protein interactions, which have traditionally been dismissed as undruggable due to their broad, flat surfaces that are difficult for conventional small molecules to bind effectively.
Additionally, Anew Labs introduced AnewOmni, a generative AI framework trained on five million biomolecular complexes. This technology claims to be the first capable of designing functional molecules across various biological scales, positioning ByteDance among forward-thinking entities in the AI-driven drug discovery space, alongside companies like Isomorphic Labs and Insilico Medicine.
Why it matters
The IL-17 protein plays a central role in autoimmune conditions including psoriasis, rheumatoid arthritis, and ankylosing spondylitis. Existing therapies employ injectable antibodies that are highly effective but costly and inconvenient for patients. The ability to develop oral small molecule drugs capable of inhibiting such targets could dramatically improve patient compliance and reduce healthcare costs.
Anew Labs’ accomplishment signals a breakthrough in overcoming the limitations pharmaceutical companies have faced for decades with protein-protein interactions. By harnessing generative AI, they may unlock a new class of therapeutics for previously intractable targets, potentially transforming treatment paradigms in immunology and beyond.
What to watch next
Following their Boston presentation, Anew Labs plans to participate in the BIO International Convention in San Diego, highlighting intentions to further reveal advancements and pipeline progress. Their leadership is also scheduled to present at specialized scientific events in Europe, signaling an ongoing commitment to engage the global scientific community.
Market observers should closely monitor Anew Labs’ clinical development stages and potential partnerships, as success in oral small molecule therapies for autoimmune diseases could disrupt existing biologics markets. The interplay between cutting-edge AI technologies and drug discovery will be a critical area for investors, researchers, and healthcare providers moving forward.